3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Small Cell Lung Carcinoma
5
Melanoma
5
Neoplasm Metastasis
4
Neoplasms
3
Brain Neoplasms
3
Thymus Neoplasms
2
Pancreatic Neoplasms
2
Locally Advanced Non-small Cell Lung Cancer
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Interventions
pembrolizumab
12
Nivolumab
4
fludarabine
3
Gemcitabine
3
Drug Therapy
3
Cisplatin
3
spartalizumab
2
budigalimab
2
Injections
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
zenocutuzumab
1
venetoclax
1
ulixertinib
1
tocilizumab
1
tislelizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
niraparib
1
neratinib
1
milademetan
1
margetuximab
1
erdafitinib
1
entrectinib
1
cobimetinib
1
cediranib
1
bemarituzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Immunotherapy
×
Thoracic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled